Cardiovascular and soft tissue repair patches market seen growing at 10.6% CAGR to 2030

The cardiovascular and soft tissue repair patches market is forecast to climb from $4.85 billion in 2025 to $8.09 billion by 2030, driven by rising cardiovascular disease cases, more surgeries and advances in biomaterials. North America led the market in 2025, while Asia-Pacific is expected to be the fastest-growing region.

Why it matters: - The market is tied to treatment for damaged heart and blood vessel tissue, where repair patches help restore structural integrity and function. - Rising cardiovascular disease rates increase demand for advanced repair solutions across cardiac surgery and regenerative medicine. - The forecast points to sustained demand through 2030 as hospitals and researchers push toward absorbable, biologic and personalized patch options.

What happened: - The Business Research Company projected the cardiovascular and soft tissue repair patches market will grow from $4.85 billion in 2025 to $5.41 billion in 2026. - The company said the market is expected to reach $8.09 billion by 2030, implying a 10.6% CAGR over the forecast period. - North America held the largest market share in 2025. - Asia-Pacific is expected to be the fastest-growing regional market. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - A free sample is available here. - The full report is available here.

The details: - Cardiovascular and soft tissue repair patches are made from laboratory-grown tissue and polymers. - The patches are designed to replace or repair damaged body tissues. - The patches mechanically support injured myocardium layers and help restore the function of damaged tissue. - The products are used primarily for cardiovascular conditions. - They reinforce or substitute impaired heart or blood vessel tissues to support structural integrity and physiological function. - Historical growth was supported by congenital heart defects, more cardiovascular surgeries, wider use of synthetic repair patches, biomaterial innovation and more specialized cardiac surgery centers. - Forecast growth is expected to come from regenerative cardiovascular therapies, investment in tissue engineering research, more sophisticated cardiac reconstruction procedures, absorbable patch materials and personalized repair options. - Reported market trends include more biologic repair patch usage, greater reliance on tissue-engineered materials, growth in minimally invasive patch implantation and more focus on biocompatibility and tissue healing. - The report’s 2026 edition adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technology and future trend analysis, plus updated graphics and tables.

Between the lines: - The market forecast reflects a shift from traditional repair toward more regenerative and biologically compatible materials. - The emphasis on minimally invasive implantation suggests the patch market is moving toward procedures that can reduce recovery burden and broaden clinical adoption. - The rise in U.S. cardiovascular mortality underscores why repair technologies are getting more attention from both care providers and market researchers. - The U.S. age-adjusted death rate from cardiovascular disease rose to 233.3 per 100,000 in January 2024, up 4.0% from 224.4 per 100,000 in 2023, according to the American Heart Association.

What's next: - Market growth will likely depend on adoption of regenerative cardiovascular therapies and continued tissue engineering research. - The report points to more demand for absorbable and personalized patch materials as cardiac reconstruction advances. - Asia-Pacific’s expected growth suggests the next wave of market expansion may come from outside North America.

The bottom line: - Cardiovascular and soft tissue repair patches are moving from a niche surgical product into a fast-growing global market shaped by chronic disease, biomaterials innovation and regenerative medicine.